Atossa Genetics is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions.

We believe our innovative therapies and delivery methods can transform breast cancer treatment– with the goals of preventing breast cancer from developing in the first place to increasing the odds of surviving for those who do develop this deadly disease.

Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year.

Tamoxifen has been widely used for over 30 years for breast cancer.  Additional research has shown that it is the metabolites of tamoxifen, of which endoxifen is the most active, that have potential therapeutic value.

We are the only company in the WORLD attempting to conquer breast cancer the way we are:

  • The best way to treat a disease is to prevent it in the first place.”  We are developing a topical drug, a lotion applied to each breast, to treat a condition known as high breast density.  Third-party studies have shown that high breast density increases the risk of developing breast cancer in some women. Breast density is diagnosed by mammography and approximately 10 million women have high density in the U.S. Tamoxifen has been demonstrated to reduce density and the incidence of breast cancer.  However, tamoxifen can have serious side effects because, as a drug taken orally, it is delivered “systemically” meaning it travels throughout the body to other areas the drug is not needed. The goal with our topical endoxifen program is to treat high breast density with a local, topical drug.
  • My biggest worry is that my breast cancer will return.”  We are also developing an oral formulation of endoxifen for breast cancer survivors who are otherwise recommended to take tamoxifen, the most commonly recommended FDA-approved drug to reduce the risk of cancer recurrence.  Tamoxifen, however, does not work for up to 50% of these patients.  Our goal with this program is to reduce the number of patients who may get breast cancer again, even after initial treatment, by providing a drug for those who may not fully benefit from tamoxifen.
  • Why am I receiving a needle injection – my cancer is in the breast, not the buttock.”  We are also developing a new way to deliver pharmaceuticals – through microcatheters (small tubes that can be inserted with anesthetic, through the nipple) so that pharmaceuticals can be targeted to the tissue where breast cancer actually grows.

Our proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. All objectives from the topical arm of this study were successfully met and we reported results from the oral arm of this study on October 25, 2017.  Our patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.

More information about our programs can be found on this website under “Our Programs.”